New cancer Drug's interaction with common meds under microscope

NCT ID NCT06575933

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without calderasib. The goal is to see if calderasib affects their breakdown, which could inform future dosing recommendations for people with non-small cell lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: calderasib (MK-1084)
What this could lead to: If successful, this study will help doctors understand how calderasib interacts with other drugs, leading to safer dosing guidelines for people with non-small cell lung cancer.
What could go wrong: This is an early-phase study in 28 healthy volunteers, not patients. It only measures drug levels, not whether calderasib works for cancer. Results may not predict real-world effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Celerion ( Site 0001)

Tempe, Arizona, 85283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.